Current report №15/2024 Dated February 27, 2024

## NOTIFICATION

"Sopharma" AD (the Company) notifies that in pursuance of a decision of the General meeting of Holders of Warrants (GMHW) held on January 26, 2024 and decision of the Board of Directors of SOPHARMA AD from a meeting held on January 26, 2024 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art. 25 of the Articles of incorporation of the company a procedure for capital increase was launched for issuing up to 7 133 264 ordinary registered dematerialized freely transferable shares with a nominal value of BGN 1 each and issue value of BGN 4.13 for one share, under the condition that the shares of the increase are subscribed by the holders of warrants of issue with ISIN BG9200001212, in accordance with the terms and conditions described in the Prospectus for Public Offering of Warrants, confirmed by a Decision of the Financial Supervision Commission (FSC) No 804-E / 04.11.2021.

The deadline for exercising warrants set by the Board of Directors in accordance with the requirements of the LPOS and the Prospectus for Public Offering of Warrants, confirmed by FSC Decision No 804-E / 04.11.2021 started on February 2, 2024 and ended on February 23, 2024. For this period, a total of 36 applications for subscription of the shares from the increase through the exercise of warrants were submitted by 36 applicants, including 3 legal entities and 33 individuals. A total of 6 510 985 (six million five hundred ten thousand nine hundred eighty five) warrants was exercised. 6 509 485 (six million five hundred and eighty-five) shares were registered against them - with 1 500 shares less - due to the fact that a request submitted by an individual has not been paid to the special bank account of "SOPHARMA" AD within the established period.

The persons who have the right to participate in the capital increase of SOPHARMA AD by exercising the warrants were those who acquired warrants 5 working days after the later date between the date of disclosure of the under Art. 89t, para. 2 from LPOS on the website of X3news.com Information Agency, on the website of SOPHARMA AD and the investment mediator selected to serve the capital increase at the latest. The issue price of the subscribed shares amounts to a total of BGN 26 884 173.05 (twenty-six million eight hundred eighty-four thousand one hundred seventy-three leva and 5 stotinki).

During the period for subscription, including during the exercise of the warrants and the subscription of the shares, the Company has encountered no difficulties, disputes or similar issues. The subscription is considered successful.

A procedure for registration of the capital increase in the Commercial Register, in the registers of the Central Depository AD, the Financial Supervision Commission, etc. is forthcoming.

**Ognian** Donev